Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CPX-351 monotherapy in post-myeloproliferative neoplasm acute myeloid leukemia
2021-002042-32Phase 2Completed
- Sponsor
- Filo
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Filo. Primary endpoint: Complete remission rate (CR/CRi). Started Jul 2021; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-002042-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002042-32.